Recursion Pharmaceuticals, Inc. (RXRX) NASDAQ

3.32

+0.05(+1.53%)

Updated at May 08 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Najat Khan	CEO, President & Director	955,009	1985
Ben R. Taylor	Chief Financial Officer & President of Recursion UK	669,109	1977
David J. Mauro	Advisor	793,399	1965
Christopher C. Gibson	Co-Founder, Chairman & Interim Executive Advisor	860,270	1983
David Hallett	Chief Scientific Officer	0	1969
Elizabeth Bruckheimer	Vice President of Clinical Development	0	N/A
Benjamin Mabey	Chief Technology Officer	0	1983
Matthew Kinn	Chief Business Officer	0	N/A
Nathan Hatfield	Chief Legal Officer & Corporate Secretary	0	N/A
Ryan Kelly	Chief Communications Officer	0	N/A
Erica Fox	Chief People and Impact Officer	0	N/A
Kristen Rushton	Chief Operating Officer	0	N/A

Name

Title

Pay

Year Born

Najat Khan

CEO, President & Director

955,009

1985

Ben R. Taylor

Chief Financial Officer & President of Recursion UK

669,109

1977

David J. Mauro

Advisor

793,399

1965

Christopher C. Gibson

Co-Founder, Chairman & Interim Executive Advisor

860,270

1983

David Hallett

Chief Scientific Officer

1969

Elizabeth Bruckheimer

Vice President of Clinical Development

N/A

Benjamin Mabey

Chief Technology Officer

1983

Matthew Kinn

Chief Business Officer

N/A

Nathan Hatfield

Chief Legal Officer & Corporate Secretary

N/A

Ryan Kelly

Chief Communications Officer

N/A

Erica Fox

Chief People and Impact Officer

N/A

Kristen Rushton

Chief Operating Officer

N/A

Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.